Marksans Pharma: ₹8,476 Cr Market Cap – 74% OTC, 26% Rx, and 100% Cash-Loaded

1. At a Glance

Marksans Pharma is a formulation-focused pharma company with a strong OTC tilt — 74% of FY24 revenue comes from over-the-counter products and 26% from prescription (Rx) drugs. It serves multiple therapeutic areas — pain, cough & cold, digestive, vitamins, skin, cardiovascular, CNS, anti-allergy, and oncology. Despite delivering 26% profit CAGR over 5 years and holding ₹711 Cr in cash, the stock is down ~5% in a year and trades at a P/E of 24.2.

2. Introduction

Founded with a focus on formulations rather than raw APIs, Marksans carved out a niche in branded and generic OTC products. The strategy has worked in terms of profitability but leaves it vulnerable to retail demand swings in key export markets like the US, UK, and Australia.

The company’s growth over the last 5 years has been impressive, but the Q1 FY26 numbers show a sales slowdown (-11% QoQ), reminding investors that even cash-rich pharma businesses can face temporary prescription refills.

3. Business Model (WTF Do They Even Do?)

Marksans is all about formulation manufacturing:

OTC (74%) – Vitamins, digestive aids, cough & cold, skin treatments.
Rx (26%) – Chronic therapies like CNS, cardiovascular, oncology, anti-diabetic.
Geographies – Major exports to regulated markets (US FDA, UK MHRA approvals in place).
Distribution – Mix of branded generics and private label supply to large retailers/pharmacy chains.

4. Financials Overview

TTM Revenue: ₹2,652 Cr
TTM Net Profit: ₹352 Cr
EBITDA Margin: ~19%
ROCE: 20.0% | ROE: 16.8%
P/E: 24.2 | Book Value: ₹54.4

Recalculating P/E using Q1 FY26 annualised EPS:

Q1 EPS = ₹1.29 → Annualised = ₹5.16 → P/E ≈ 36.2 (higher than static due to lower quarterly profits).

5. Valuation – Fair Value RANGE

Method	Basis	FV Range (₹)
P/E Multiple	Sector avg ~25x on EPS ₹5.16	125 – 140
EV/EBITDA	Sector avg 14x on EBITDA ₹502 Cr	160 – 185
DCF (10% disc., 10% growth)	Cash flows	150 – 180

Fair Value Range: ₹125 – ₹185
This FV range is for educational purposes only and is not investment advice.

6. What’s Cooking – News, Triggers, Drama

Q1 FY26: Revenue ₹620 Cr (+5% YoY), EBITDA ₹100 Cr, PAT ₹58 Cr.
Cash pile: ₹711 Cr — a potential war chest for acquisitions or buybacks.
Promoter holding stable at 43.87%, but down ~4.4% in 3 years.
FII interest peaked at 22.19% (Mar 2025), now 19.89%.

7. Balance Sheet – Auditor’s Roast

FY25 (₹ Cr)	Assets	Liabilities	Net Worth	Borrowings

To Read Full 16 Point